AzTrials
AzTrials

Postoperative Pain After Total Knee ArthroplastyNCT07588958

Genicular Nerve Versus Adductor Canal Block for Postoperative Analgesia

A study testing Spinal Anesthesia with Bupivacaine and Fentanyl, Genicular nerve block with bupivacaine and Adductor Canal Block (ACB) Only in people with Postoperative Pain After Total Knee Arthroplasty, run by Zagazig University at 1 site in Egypt.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Severe postoperative pain following total knee arthroplasty (TKA ) has been shown to negatively affect early mobilization, physical rehabilitation, time to discharge, and overall post-operative recovery.Therefore, reducing postoperative pain and early mobilization has become critical in reducing early mortality… Read more about this study

Who is it for?
Ages 65 years and older
What is being tested?
Spinal Anesthesia with Bupivacaine and Fentanyl, Genicular nerve block with bupivacaine and Adductor Canal Block (ACB) Only
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
42 participants
Where
1 siteEgypt
Study dates
1 Oct 2023to 19 Jun 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • Patient acceptance.
  • Sex: both; male and female.
  • Age: over 65 years old.
  • American society of anesthesiologists (ASA): II .
  • Body mass index (BMI) less than 35 kg/m2.
  • Operation : elective unilateral TKA.
  • Duration of surgery : 2-3 hours.

Who cannot join

  • History of allergy to local anesthetics (lidocaine or bupivicaine).
  • Coexisting hematologic disorders or malnourished patient.
  • Pre-existing major organ dysfunction including hepatic or renal failure, and left ventricular ejection fraction <30%
  • Peripheral neuropathy.
  • Patients with a diagnosis of cognitive impairment or significant psychiatric illness.
  • Skin infection at site of block.
  • Contraindication to spinal anesthesia as coagulopathy and infection at site of injection.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Faculty of Medicine - Zagazig University

    Zagazig, Alsharqia, 4115

Other trials in Egypt

About this study

Official title: Genicular Nerve Versus Adductor Canal Block for Postoperative Analgesia in Patients Undergoing Total Knee Arthroplasty

Severe postoperative pain following total knee arthroplasty (TKA ) has been shown to negatively affect early mobilization, physical rehabilitation, time to discharge, and overall post-operative recovery.Therefore, reducing postoperative pain and early mobilization has become critical in reducing early mortality, preventing future chronic pain, and limiting the use of opioids The adductor canal block (ACB) has been found to be an excellent alternative to the FNB, providing adequate analgesia to the anterior knee compartment while enabling an improved postoperative range of motion by sparing motor branches to the quadriceps muscles . However, patients do not achieve adequate posterior knee analgesia as ACB pain relief is primarily limited to the anterior capsule of the knee.

Genicular nerve block (GNB) and radiofrequency ablation of genicular nerves (RFGN) were originally introduced by Choi et al. as a therapeutic alternative for chronic knee OA and were quickly adopted for use in patients undergoing TKA due to the significant pain reduction and functional improvement observed in these patients . GNBs target five main innervating branches of the knee, including the superomedial, inferomedial, superolateral, inferolateral genicular nerves, and the infrapatellar branch of the saphenous nerve.

Read the detailed description

Chronic knee osteoarthritis (OA), an epidemic among aging populations, is a leading source of chronic pain in the United States and other developed countries . The rise in prevalence of knee OA is a direct result of factors including longer life expectancy and increased body mass index (BMI). It has been reported that at least 19% of American adults aged 45 years and older are affected . Severe postoperative pain following total knee arthroplasty (TKA ) has been shown to negatively affect early mobilization, physical rehabilitation, time to discharge, and overall post-op recovery

.Therefore, reducing postoperative pain and early mobilization has become critical in reducing early mortality, preventing future chronic pain, and limiting the use of opioids . Balancing pain control with patient ambulation often proves to be a challenge due to both the motor blocking effects of many proximal nerve blocks and the often inadequate analgesia associated with more superficial periarticular injections . Therefore, numerous modalities of analgesic treatment combining different methods of nerve blockade for effective postoperative analgesia and faster functional recovery have been discussed . However, the superior technique is yet to be

determined. Successful postoperative analgesia for TKA requires careful consideration of knee innervation, with an emphasis placed on branches of the femoral nerve innervating the anterior and medical aspects of the knee and branches of the sciatic nerve innervating the posterior aspects of the knee capsule . In the context of nerve blockade, femoral nerve block (FNB) has traditionally been a critical component in the multimodal management of pain in TKA patients due to the high analgesic efficacy and the minimal risks associated. However, FNB is associated with decreased quadriceps motor strength leading to limited physical therapy (PT) participation, delayed ambulation, and discharge . The adductor canal block (ACB) has been found to be an excellent alternative to the FNB, providing adequate analgesia to the anterior knee compartment while enabling an improved postoperative range of motion by sparing motor branches to the quadriceps muscles . However, patients do not achieve adequate posterior knee analgesia as ACB pain relief is primarily limited to the anterior capsule of the knee.

Genicular nerve block (GNB) and radiofrequency ablation of genicular nerves (RFGN) were originally introduced by Choi et al. as a therapeutic alternative for chronic knee OA and were quickly adopted for use in patients undergoing TKA due to the significant pain reduction and functional improvement observed in these patients . GNBs target five main innervating branches of the knee, including the superomedial, inferomedial, superolateral, inferolateral genicular nerves, and the infrapatellar branch of the saphenous nerve. Several bony landmarks surrounding these nerves aid in proper needle placement under fluoroscopic guidance . The GNB has a motor-sparing effect that is desirable for early ambulation postoperatively, better PT, and earlier discharge .

Being tested
Spinal Anesthesia with Bupivacaine and Fentanyl, Genicular nerve block with bupivacaine, Adductor Canal Block (ACB) Only
Keywords
genicular nerve block, Adductor canal block, postoperative analgesia, total knee arthroplasty

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Spinal Anesthesia with Bupivacaine and FentanylOther

    spinal anesthesia will be given (under complete aseptic conditions) at the level of L3/4 while the patient in the sitting position using a spinal needle 25 G x 3.5 inches with injection of hyperbaric bupivacaine 0.5% 3ml plus fentanyl 25 microgram .

  • Genicular nerve block with bupivacaineOther

    For the superomedial genicular nerve, a linear transducer will be placed along the longitudinal plane of the femur to visualize vastus medialis, the distal femur, and the genicular artery. Using an in-plane technique, a 10-cm echogenic 21-gauge needle will be advanced in the cephalad to the caudad direction until the needle contacted femoral shaft, just cephalad to the genicular artery, and 5 ml of 0.25% bupivacaine will be injected to spread along the femoral periosteum. This same technique, using 5 ml of 0.25% bupivacaine, will be used in a mirror image on the lateral epicondyle to block the superolateral genicular nerve.

    To target the inferomedial genicular nerve, a linear transducer will be placed in the sagittal plane on the anterior medial tibia.

  • Adductor Canal Block (ACB) OnlyOther

    The transducer will be placed anteromedially midway between inguinal crease and medial condyle to identify sartorius muscle. Probe will be positioned perpendicular to the femoral artery and using in-plane technique with needle directed from lateral to medial to deposit local anesthetic under sartorius and around the femoral artery. 15ml bupivacaine 0.25% will be injected

Study groups in NCT07588958
Study groupRoleWhat they receive
control groupOtherReceive spinal anesthesia
Receives: Other: Spinal Anesthesia with Bupivacaine and Fentanyl
Genicular nerve block groupActive comparatorReceive Genicular Nerve Block
Receives: Other: Genicular nerve block with bupivacaine
Adductor canal block groupActive comparatorReceive Adductor canal block
Receives: Other: Adductor Canal Block (ACB) Only

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. changes of pain assessment

    visual analogue scale

    Measured: time frame ( at PACU, 2 hours (h ) , 4 , 8 , 12 , 16 , 24 hours postoperatively )

Secondary outcomes (1)
  1. Modified Bromage scale

    no motor nerveblock in the lower extremity = 0 point; the affected limb cannot lift the leg = 1 point; failure to bend the knee of the affected limb = 2 points; and failure to bend the ankle = 3points

    Measured: at PACU, 3 hours and 6 hours postoperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 May 2026
  2. Study start1 Oct 2023
  3. Primary completion6 May 2026 (estimated)
  4. Study completion19 Jun 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
42 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07588958
Sponsor's protocol ID
10793-14/5-2023
Status last verified
May 2026
First submitted
9 May 2026
Last updated
15 May 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Planned after completion of the study and publications

Questions about this trial

What is this clinical trial studying?

A study testing Spinal Anesthesia with Bupivacaine and Fentanyl, Genicular nerve block with bupivacaine and Adductor Canal Block (ACB) Only in people with Postoperative Pain After Total Knee Arthroplasty, run by Zagazig University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 15 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

changes of pain assessment (time frame: time frame ( at PACU, 2 hours (h ) , 4 , 8 , 12 , 16 , 24 hours postoperatively )). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in